retatrutide peptide eli lilly 🚨🚨🚨@EliLillyandCompany ANNOUNCES NEW PEPTIDE! COULD CHANGE THE ENTIRE GAME! Eli Lilly stock jumps on

However, CMS clarified in a memo dated March 20, 2024, that anti-obesity medications that receive FDA approval for an additional medically accepted indication can be considered a Part D drug for that specific use. As of August 19, 2024, the only GLP-1 RA this applies to is Wegovy, which, in addition to its obesity indication, is also indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight

Some small studies and anecdotal clinical reports suggest that the combination may lead to a more significant reduction in body weight than either drug alone

R., Diaz R., Lakshmanan M., Pais P., Probstfield J., Riesmeyer J

[DOI] [PubMed] [Google Scholar] 37.Nosso G, Griffo E, Cotugno M, et al

By purchasing this material, the purchaser acknowledges that the product will be used solely within a lawful laboratory research environment by qualified professionals or researchers.